Mepacrine

Drug Profile

Mepacrine

Alternative Names: 9-aminoacridine; Atabrine dihydrochloride; CBL 0102; Curaxin CBL0102; Quinacrine; SN 390

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Cleveland BioLabs
  • Developer Incuron; National Cancer Institute (USA)
  • Class Aminoacridines; Antimalarials; Antineoplastics; Antiprotozoals; Small molecules
  • Mechanism of Action SSRP1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Liver cancer; Liver metastases; Non-small cell lung cancer

Most Recent Events

  • 23 May 2016 Mepacrine is still in phase I trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 23 May 2016 Phase-I development for Liver cancer and Liver metastases is ongoing in Russia (PO)
  • 23 May 2016 Phase-II development for Prostate cancer (Hormone refractory) is ongoing in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top